Disc Medicine, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel treatments for hematologic disorders. Its programs include Bitopertin, DISC-0974, and DISC-3405. The company was founded in October 2017 and is headquartered in Watertown, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Gemini Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Gemini Therapeutics Inc market cap is $679.96M.
What is the 52-week high for Gemini Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Gemini Therapeutics Inc 52 week high is $77.60 as of September 20, 2025.
What is the 52-week low for Gemini Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Gemini Therapeutics Inc 52 week low is $25.60 as of September 20, 2025.
What is Gemini Therapeutics Inc stock price today?
Gemini Therapeutics Inc stock price today is $28.21.
What was Gemini Therapeutics Inc stock price yesterday?
Gemini Therapeutics Inc stock price yesterday was $27.55.
What is the PE ratio of Gemini Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Gemini Therapeutics Inc’s P/E ratio is -7.86.
What is the Price-to-Book ratio of Gemini Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Gemini Therapeutics Inc P/B ratio is 1.8526.
What is Gemini Therapeutics Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Gemini Therapeutics Inc's EBITDA is -9.38.
What is the 50-day moving average of Gemini Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Gemini Therapeutics Inc 50-day moving average is $51.07.
